Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.

Campone M, Im SA, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Cortés J, De Laurentiis M, Arteaga CL, Jiang Z, Jonat W, Le Mouhaër S, Sankaran B, Bourdeau L, El-Hashimy M, Sellami D, Baselga J.

Eur J Cancer. 2018 Sep 18;103:147-154. doi: 10.1016/j.ejca.2018.08.002. [Epub ahead of print]

PMID:
30241001
2.

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial.

Bardia A, Parton M, Kümmel S, Estévez LG, Huang CS, Cortés J, Ruiz-Borrego M, Telli ML, Martin-Martorell P, López R, Beck JT, Ismail-Khan R, Chen SC, Hurvitz SA, Mayer IA, Carreon D, Cameron S, Liao S, Baselga J, Kim SB.

J Clin Oncol. 2018 Sep 20:JCO2017748392. doi: 10.1200/JCO.2017.74.8392. [Epub ahead of print]

PMID:
30235087
3.

Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.

Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK.

Ann Oncol. 2018 Aug 15. doi: 10.1093/annonc/mdy257. [Epub ahead of print]

PMID:
30124753
4.

Advances in the use of PARP inhibitor therapy for breast cancer.

McCann KE, Hurvitz SA.

Drugs Context. 2018 Aug 8;7:212540. doi: 10.7573/dic.212540. eCollection 2018. Review.

5.

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL.

N Engl J Med. 2018 Aug 23;379(8):753-763. doi: 10.1056/NEJMoa1802905. Epub 2018 Aug 15.

PMID:
30110579
6.

A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.

Carducci M, Shaheen M, Markman B, Hurvitz S, Mahadevan D, Kotasek D, Goodman OB Jr, Rasmussen E, Chow V, Juan G, Friberg GR, Gamelin E, Vogl FD, Desai J.

Invest New Drugs. 2018 Jul 7. doi: 10.1007/s10637-018-0625-6. [Epub ahead of print]

PMID:
29980894
7.

Targeted Therapy for Premenopausal Women with HR+, HER2- Advanced Breast Cancer: Focus on Special Considerations and Latest Advances.

Bardia A, Hurvitz S.

Clin Cancer Res. 2018 Jun 8. doi: 10.1158/1078-0432.CCR-18-0162. [Epub ahead of print] Review.

PMID:
29884743
8.

Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.

Jerusalem G, de Boer RH, Hurvitz S, Yardley DA, Kovalenko E, Ejlertsen B, Blau S, Özgüroglu M, Landherr L, Ewertz M, Taran T, Fan J, Noel-Baron F, Louveau AL, Burris H.

JAMA Oncol. 2018 Jun 3:e182262. doi: 10.1001/jamaoncol.2018.2262. [Epub ahead of print]

PMID:
29862411
9.

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.

Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS.

Lancet Oncol. 2018 Jul;19(7):904-915. doi: 10.1016/S1470-2045(18)30292-4. Epub 2018 May 24.

PMID:
29804902
10.

Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer.

O'Brien N, Conklin D, Beckmann R, Luo T, Chau K, Thomas J, Mc Nulty A, Marchal C, Kalous O, von Euw E, Hurvitz S, Mockbee C, Slamon DJ.

Mol Cancer Ther. 2018 May;17(5):897-907. doi: 10.1158/1535-7163.MCT-17-0290. Epub 2018 Feb 26.

PMID:
29483214
11.

Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer.

Formenti SC, Lee P, Adams S, Goldberg JD, Li X, Xie MW, Ratikan JA, Felix C, Hwang L, Faull KF, Sayre JW, Hurvitz S, Glaspy JA, Comin-Anduix B, Demaria S, Schaue D, McBride WH.

Clin Cancer Res. 2018 Jun 1;24(11):2493-2504. doi: 10.1158/1078-0432.CCR-17-3322. Epub 2018 Feb 23.

PMID:
29476019
12.

Harnessing the immune system in the battle against breast cancer.

Nakasone ES, Hurvitz SA, McCann KE.

Drugs Context. 2018 Feb 12;7:212520. doi: 10.7573/dic.212520. eCollection 2018. Review.

13.

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.

Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D.

Lancet Oncol. 2018 Jan;19(1):115-126. doi: 10.1016/S1470-2045(17)30716-7. Epub 2017 Nov 23.

PMID:
29175149
14.

Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer.

Hegde JV, Wang X, Attai DJ, DiNome ML, Kusske A, Hoyt AC, Hurvitz SA, Weidhaas JB, Steinberg ML, McCloskey SA.

Clin Breast Cancer. 2018 Apr;18(2):e205-e218. doi: 10.1016/j.clbc.2017.09.010. Epub 2017 Sep 27.

PMID:
29050918
15.

Effect and Efficiency of an Embedded Palliative Care Nurse Practitioner in an Oncology Clinic.

Walling AM, D'Ambruoso SF, Malin JL, Hurvitz S, Zisser A, Coscarelli A, Clarke R, Hackbarth A, Pietras C, Watts F, Ferrell B, Skootsky S, Wenger NS.

J Oncol Pract. 2017 Sep;13(9):e792-e799. doi: 10.1200/JOP.2017.020990. Epub 2017 Aug 16.

PMID:
28813191
16.

Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer.

Hegde JV, Wang X, Attai DJ, DiNome ML, Kusske A, Hoyt AC, Hurvitz SA, Weidhaas JB, Steinberg ML, McCloskey SA.

Breast Cancer Res Treat. 2017 Nov;166(1):145-156. doi: 10.1007/s10549-017-4392-4. Epub 2017 Jul 12.

PMID:
28702891
17.

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M.

Lancet Oncol. 2017 Jul;18(7):904-916. doi: 10.1016/S1470-2045(17)30376-5. Epub 2017 May 30.

18.

Optimal Management of Early and Advanced HER2 Breast Cancer.

Hurvitz SA, Gelmon KA, Tolaney SM.

Am Soc Clin Oncol Educ Book. 2017;37:76-92. doi: 10.14694/EDBK_175630. Review.

19.

Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.

Toi M, Shao Z, Hurvitz S, Tseng LM, Zhang Q, Shen K, Liu D, Feng J, Xu B, Wang X, Lee KS, Ng TY, Ridolfi A, Noel-Baron F, Ringeisen F, Jiang Z.

Breast Cancer Res. 2017 Apr 11;19(1):47. doi: 10.1186/s13058-017-0839-0.

20.

Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer.

Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A, Park G, Mitchel J, Bågeman E, D'Agostino RB Jr, Ver Hoeve ES, Esserman L, Cigler T.

JAMA. 2017 Feb 14;317(6):606-614. doi: 10.1001/jama.2016.21038.

21.

A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity.

Huang Y, Burns DJ, Rich BE, MacNeil IA, Dandapat A, Soltani SM, Myhre S, Sullivan BF, Furcht LT, Lange CA, Hurvitz SA, Laing LG.

Oncotarget. 2016 Nov 29;7(48):78577-78590. doi: 10.18632/oncotarget.12480.

22.

Increasing Appropriate BRCA1/2 Mutation Testing: The Role of Family History Documentation and Genetic Counseling in a Multidisciplinary Clinic.

Kishan AU, Gomez CL, Dawson NA, Dvorak R, Foster NM, Hoyt A, Hurvitz SA, Kusske A, Silver EL, Tseng C, McCloskey SA.

Ann Surg Oncol. 2016 Dec;23(Suppl 5):634-641. Epub 2016 Sep 12.

PMID:
27619940
23.

Use of a Shared Mental Model by a Team Composed of Oncology, Palliative Care, and Supportive Care Clinicians to Facilitate Shared Decision Making in a Patient With Advanced Cancer.

D'Ambruoso SF, Coscarelli A, Hurvitz S, Wenger N, Coniglio D, Donaldson D, Pietras C, Walling AM.

J Oncol Pract. 2016 Nov;12(11):1039-1045. Epub 2016 Oct 31.

24.

Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.

Zhang B, Hurvitz S.

Clin Adv Hematol Oncol. 2016 Jul;14(7):520-30. Review.

PMID:
27379947
25.

Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.

Curigliano G, Gómez Pardo P, Meric-Bernstam F, Conte P, Lolkema MP, Beck JT, Bardia A, Martínez García M, Penault-Llorca F, Dhuria S, Tang Z, Solovieff N, Miller M, Di Tomaso E, Hurvitz SA.

Breast. 2016 Aug;28:191-8. doi: 10.1016/j.breast.2016.06.008. Epub 2016 Jun 20.

26.

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.

Miller K, Cortes J, Hurvitz SA, Krop IE, Tripathy D, Verma S, Riahi K, Reynolds JG, Wickham TJ, Molnar I, Yardley DA.

BMC Cancer. 2016 Jun 3;16:352. doi: 10.1186/s12885-016-2385-z.

27.

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.

André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H, He W, Robinson D, Riester M, Taran T, Chen D, Slamon D.

J Clin Oncol. 2016 Jun 20;34(18):2115-24. doi: 10.1200/JCO.2015.63.9161. Epub 2016 Apr 18.

PMID:
27091708
28.

MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.

Hong CS, Graham NA, Gu W, Espindola Camacho C, Mah V, Maresh EL, Alavi M, Bagryanova L, Krotee PAL, Gardner BK, Behbahan IS, Horvath S, Chia D, Mellinghoff IK, Hurvitz SA, Dubinett SM, Critchlow SE, Kurdistani SK, Goodglick L, Braas D, Graeber TG, Christofk HR.

Cell Rep. 2016 Feb 23;14(7):1590-1601. doi: 10.1016/j.celrep.2016.01.057. Epub 2016 Feb 11.

29.

Statistical controversies in clinical research: statistical significance-too much of a good thing ….

Buyse M, Hurvitz SA, Andre F, Jiang Z, Burris HA, Toi M, Eiermann W, Lindsay MA, Slamon D.

Ann Oncol. 2016 May;27(5):760-2. doi: 10.1093/annonc/mdw047. Epub 2016 Feb 9. Review.

PMID:
26861602
30.

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.

Harbeck N, Huang CS, Hurvitz S, Yeh DC, Shao Z, Im SA, Jung KH, Shen K, Ro J, Jassem J, Zhang Q, Im YH, Wojtukiewicz M, Sun Q, Chen SC, Goeldner RG, Uttenreuther-Fischer M, Xu B, Piccart-Gebhart M; LUX-Breast 1 study group.

Lancet Oncol. 2016 Mar;17(3):357-66. doi: 10.1016/S1470-2045(15)00540-9. Epub 2016 Jan 26.

PMID:
26822398
31.

Triple-negative breast cancer: advancements in characterization and treatment approach.

Hurvitz S, Mead M.

Curr Opin Obstet Gynecol. 2016 Feb;28(1):59-69. doi: 10.1097/GCO.0000000000000239. Review.

PMID:
26694831
32.

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.

Cortés J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, Le Rhun E, Espié M, Kim SB, Schneeweiss A, Sohn JH, Nabholtz JM, Kellokumpu-Lehtinen PL, Taguchi J, Piacentini F, Ciruelos E, Bono P, Ould-Kaci M, Roux F, Joensuu H.

Lancet Oncol. 2015 Dec;16(16):1700-10. doi: 10.1016/S1470-2045(15)00373-3. Epub 2015 Nov 17.

PMID:
26596672
33.

NatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancer.

Korner EJ, Morris A, Allen IE, Hurvitz S, Beattie MS, Kalesan B.

Syst Rev. 2015 Oct 1;4:133. doi: 10.1186/s13643-015-0118-z. Review.

34.

Breast cancer: The debate over post-mastectomy radiotherapy should continue.

Oliai C, Hurvitz SA.

Nat Rev Clin Oncol. 2015 Oct;12(10):567-8. doi: 10.1038/nrclinonc.2015.147. Epub 2015 Sep 1. No abstract available.

PMID:
26323387
35.

SERUM THYROTROPIN CONCENTRATIONS ARE NOT PREDICTIVE OF AGGRESSIVE BREAST CANCER BIOLOGY IN EUTHYROID INDIVIDUALS.

Villa NM, Li N, Yeh MW, Hurvitz SA, Dawson NA, Leung AM.

Endocr Pract. 2015 Sep;21(9):1040-5. doi: 10.4158/EP15733.OR. Epub 2015 Jun 29.

36.

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.

Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay MA, Rao S, Pacaud LB, Taran T, Slamon D.

Lancet Oncol. 2015 Jul;16(7):816-29. doi: 10.1016/S1470-2045(15)00051-0. Epub 2015 Jun 16.

PMID:
26092818
37.

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.

Diéras V, Wildiers H, Jassem J, Dirix LY, Guastalla JP, Bono P, Hurvitz SA, Gonçalves A, Romieu G, Limentani SA, Jerusalem G, Lakshmaiah KC, Roché H, Sánchez-Rovira P, Pienkowski T, Seguí Palmer MÁ, Li A, Sun YN, Pickett CA, Slamon DJ.

Breast. 2015 Jun;24(3):182-90. doi: 10.1016/j.breast.2014.11.003. Epub 2015 Mar 5.

PMID:
25747197
38.

In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.

Hurvitz SA, Kalous O, Conklin D, Desai AJ, Dering J, Anderson L, O'Brien NA, Kolarova T, Finn RS, Linnartz R, Chen D, Slamon DJ.

Breast Cancer Res Treat. 2015 Feb;149(3):669-80. doi: 10.1007/s10549-015-3282-x. Epub 2015 Feb 8.

PMID:
25663547
39.

Symptom burden and quality of life among women with HER2(+) metastatic breast cancer.

Mayer M, Lang K, Hurvitz S, Lalla D, Federico V, Brammer M, Menzin J, Tripathy D.

Breast J. 2015 Mar-Apr;21(2):208-10. doi: 10.1111/tbj.12374. Epub 2015 Feb 6. No abstract available.

PMID:
25655357
40.

Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates.

Wong DJ, Hurvitz SA.

Ann Transl Med. 2014 Dec;2(12):122. doi: 10.3978/j.issn.2305-5839.2014.08.13. Review.

41.

Estrogen receptor (ER)α-regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progression.

Drew BG, Hamidi H, Zhou Z, Villanueva CJ, Krum SA, Calkin AC, Parks BW, Ribas V, Kalajian NY, Phun J, Daraei P, Christofk HR, Hewitt SC, Korach KS, Tontonoz P, Lusis AJ, Slamon DJ, Hurvitz SA, Hevener AL.

J Biol Chem. 2015 Feb 27;290(9):5566-81. doi: 10.1074/jbc.M114.606459. Epub 2014 Dec 2.

42.

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine.

Sadeghi S, Olevsky O, Hurvitz SA.

Pharmgenomics Pers Med. 2014 Oct 15;7:329-38. doi: 10.2147/PGPM.S47524. eCollection 2014. Review.

43.
44.

Cardiotoxicity of targeted agents in oncology: a medical oncology perspective.

Wong DJ, Hurvitz SA.

Oncology (Williston Park). 2014 Jun;28(6):490-2. No abstract available.

45.

Antibody-drug conjugates: an emerging modality for the treatment of cancer.

Leal M, Sapra P, Hurvitz SA, Senter P, Wahl A, Schutten M, Shah DK, Haddish-Berhane N, Kabbarah O.

Ann N Y Acad Sci. 2014 Aug;1321:41-54. doi: 10.1111/nyas.12499. Review.

PMID:
25123209
46.

Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.

Hurvitz S, Guerin A, Brammer M, Guardino E, Zhou ZY, Latremouille Viau D, Wu EQ, Lalla D.

Oncologist. 2014 Sep;19(9):901-8. doi: 10.1634/theoncologist.2014-0059. Epub 2014 Aug 1.

47.

Treatment of trastuzumab-refractory, HER2-positive metastatic breast cancer.

Hurvitz S.

Clin Adv Hematol Oncol. 2014 Apr;12(4):260-2. No abstract available.

PMID:
25003356
48.

Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens.

Hansen RN, Ramsey SD, Lalla D, Masaquel A, Kamath T, Brammer M, Hurvitz SA, Sullivan SD.

Springerplus. 2014 May 21;3:259. doi: 10.1186/2193-1801-3-259. eCollection 2014.

50.

The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Tripathy D, Rugo HS, Kaufman PA, Swain S, O'Shaughnessy J, Jahanzeb M, Mason G, Beattie M, Yoo B, Lai C, Masaquel A, Hurvitz S.

BMC Cancer. 2014 May 2;14:307. doi: 10.1186/1471-2407-14-307.

Supplemental Content

Loading ...
Support Center